Interestingly, in 71% of IDH-mutated post-MPN AMLs, IDH mutations are associated with SRSF2 mutations; conversely, SRSF2 mutations are associated in 55% of cases with IDH mutations [71]. The gene discussed is IDH2; the disease is myeloproliferative disorder.